Dr Oliver Fisher and colleagues from Australia clarified the prognostic role of tumor protein 53 (TP53) mutations in patients with esophageal adenocarcinoma as there is a need for biomarkers that assist in guiding management for patients with esophageal adenocarcinoma.
The team conducted a systematic review using MEDLINE, Embase, PubMed and Current Contents Connect to identify studies published between 1990 and February 2015 of esophageal cancer populations that measured tumoral TP53 status, and reported hazard ratios, or adequate data for estimation of HR for survival for TP53-defined subgroups.
Risk of bias for hazard ratios estimates was assessed using prespecified criteria for the appraisal of relevant domains as defined by the Cochrane Prognosis Methods Group including adherence to Grading of Recommendations, Assessment, Development and Evaluation and REporting recommendations for tumor MARKer prognostic studies guidelines, as well as assay method used, and adjustment for standard prognostic factors.
The team identified 16 eligible studies including 888 patients were identified.
The research team found that TP53 mutations were associated with reduced survival.
A greater prognostic effect was observed in a sensitivity analysis of those studies that reported survival for esophageal adenocarcinoma-only cohorts and were assessed at low risk of bias.
Dr Lord's team concludes, "Patients with esophageal adenocarcinoma, and TP53 gene mutations have reduced overall survival compared with patients without these mutations, and this effect is independent of tumor stage."